HOTH THERAPEUTICS INC (HOTH) Fundamental Analysis & Valuation

NASDAQ:HOTH • US44148G2049

Current stock price

0.579 USD
+0.02 (+3.04%)
At close:
0.552 USD
-0.03 (-4.66%)
After Hours:

This HOTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. HOTH Profitability Analysis

1.1 Basic Checks

  • HOTH had negative earnings in the past year.
  • HOTH had a negative operating cash flow in the past year.
  • HOTH had negative earnings in each of the past 5 years.
  • HOTH had a negative operating cash flow in each of the past 5 years.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M

1.2 Ratios

  • HOTH has a Return On Assets of -164.00%. This is amonst the worse of the industry: HOTH underperforms 84.38% of its industry peers.
  • HOTH has a Return On Equity of -202.73%. This is in the lower half of the industry: HOTH underperforms 74.48% of its industry peers.
Industry RankSector Rank
ROA -164%
ROE -202.73%
ROIC N/A
ROA(3y)-117.52%
ROA(5y)-130.19%
ROE(3y)-136.92%
ROE(5y)-155.53%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

1.3 Margins

  • HOTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025

6

2. HOTH Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for HOTH has been increased compared to 1 year ago.
  • Compared to 5 years ago, HOTH has more shares outstanding
  • HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -14.33, we must say that HOTH is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -14.33, HOTH is not doing good in the industry: 77.60% of the companies in the same industry are doing better.
  • HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.33
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M -10M

2.3 Liquidity

  • HOTH has a Current Ratio of 4.72. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
  • HOTH has a Current ratio of 4.72. This is in the better half of the industry: HOTH outperforms 64.06% of its industry peers.
  • HOTH has a Quick Ratio of 4.72. This indicates that HOTH is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.72, HOTH is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.72
Quick Ratio 4.72
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

1

3. HOTH Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 32.33% over the past year.
EPS 1Y (TTM)32.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.85% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y33.13%
EPS Next 2Y9.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 2033 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

0

4. HOTH Valuation Analysis

4.1 Price/Earnings Ratio

  • HOTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.85%
EPS Next 3YN/A

0

5. HOTH Dividend Analysis

5.1 Amount

  • HOTH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

HOTH Fundamentals: All Metrics, Ratios and Statistics

HOTH THERAPEUTICS INC

NASDAQ:HOTH (4/6/2026, 8:00:02 PM)

After market: 0.552 -0.03 (-4.66%)

0.579

+0.02 (+3.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-27
Earnings (Next)05-11
Inst Owners6.36%
Inst Owner Change0%
Ins Owners3.57%
Ins Owner Change0%
Market Cap8.98M
Revenue(TTM)N/A
Net Income(TTM)-12.47M
Analysts82.86
Price Target5.1 (780.83%)
Short Float %4.5%
Short Ratio1.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-125.49%
Min EPS beat(2)-194.12%
Max EPS beat(2)-56.86%
EPS beat(4)0
Avg EPS beat(4)-67.96%
Min EPS beat(4)-194.12%
Max EPS beat(4)-1.81%
EPS beat(8)3
Avg EPS beat(8)-25.7%
EPS beat(12)7
Avg EPS beat(12)-8.02%
EPS beat(16)10
Avg EPS beat(16)-4.53%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)11.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-0.9
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -164%
ROE -202.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-117.52%
ROA(5y)-130.19%
ROE(3y)-136.92%
ROE(5y)-155.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.72
Quick Ratio 4.72
Altman-Z -14.33
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y33.13%
EPS Next 2Y9.85%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.49%
OCF growth 3YN/A
OCF growth 5YN/A

HOTH THERAPEUTICS INC / HOTH Fundamental Analysis FAQ

What is the fundamental rating for HOTH stock?

ChartMill assigns a fundamental rating of 2 / 10 to HOTH.


What is the valuation status of HOTH THERAPEUTICS INC (HOTH) stock?

ChartMill assigns a valuation rating of 0 / 10 to HOTH THERAPEUTICS INC (HOTH). This can be considered as Overvalued.


What is the profitability of HOTH stock?

HOTH THERAPEUTICS INC (HOTH) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for HOTH stock?

The Earnings per Share (EPS) of HOTH THERAPEUTICS INC (HOTH) is expected to grow by 33.13% in the next year.